388 related articles for article (PubMed ID: 16243813)
21. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.
Jin M; Gock SB; Jannetto PJ; Jentzen JM; Wong SH
J Anal Toxicol; 2005 Oct; 29(7):590-8. PubMed ID: 16419387
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.
Shih PS; Huang JD
Drug Metab Dispos; 2002 Dec; 30(12):1491-6. PubMed ID: 12433824
[TBL] [Abstract][Full Text] [Related]
23. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.
Elens L; Nieuweboer AJ; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; van Gelder T; Mathijssen RH; van Schaik RH
Pharmacogenet Genomics; 2013 Mar; 23(3):148-55. PubMed ID: 23324807
[TBL] [Abstract][Full Text] [Related]
24. Irinotecan pathway genotype analysis to predict pharmacokinetics.
Mathijssen RH; Marsh S; Karlsson MO; Xie R; Baker SD; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2003 Aug; 9(9):3246-53. PubMed ID: 12960109
[TBL] [Abstract][Full Text] [Related]
25. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo.
Lowry JA; Kearns GL; Abdel-Rahman SM; Nafziger AN; Khan IS; Kashuba AD; Schuetz EG; Bertino JS; van den Anker JN; Leeder JS
Clin Pharmacol Ther; 2003 Mar; 73(3):209-22. PubMed ID: 12621386
[TBL] [Abstract][Full Text] [Related]
26. Factors affecting cytochrome P-450 3A activity in cancer patients.
Baker SD; van Schaik RH; Rivory LP; Ten Tije AJ; Dinh K; Graveland WJ; Schenk PW; Charles KA; Clarke SJ; Carducci MA; McGuire WP; Dawkins F; Gelderblom H; Verweij J; Sparreboom A
Clin Cancer Res; 2004 Dec; 10(24):8341-50. PubMed ID: 15623611
[TBL] [Abstract][Full Text] [Related]
27. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.
Hu YF; He J; Chen GL; Wang D; Liu ZQ; Zhang C; Duan LF; Zhou HH
Clin Chim Acta; 2005 Mar; 353(1-2):187-92. PubMed ID: 15698606
[TBL] [Abstract][Full Text] [Related]
28. The CYP3A4*18 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals.
Lee SJ; Lee SS; Jeong HE; Shon JH; Ryu JY; Sunwoo YE; Liu KH; Kang W; Park YJ; Shin CM; Shin JG
Drug Metab Dispos; 2007 Nov; 35(11):2095-101. PubMed ID: 17724065
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.
Hesselink DA; van Gelder T; van Schaik RH; Balk AH; van der Heiden IP; van Dam T; van der Werf M; Weimar W; Mathot RA
Clin Pharmacol Ther; 2004 Dec; 76(6):545-56. PubMed ID: 15592326
[TBL] [Abstract][Full Text] [Related]
30. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
31. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.
Lin YS; Dowling AL; Quigley SD; Farin FM; Zhang J; Lamba J; Schuetz EG; Thummel KE
Mol Pharmacol; 2002 Jul; 62(1):162-72. PubMed ID: 12065767
[TBL] [Abstract][Full Text] [Related]
32. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.
Lee SJ; Goldstein JA
Pharmacogenomics; 2005 Jun; 6(4):357-71. PubMed ID: 16004554
[TBL] [Abstract][Full Text] [Related]
33. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
Kharasch ED; Walker A; Isoherranen N; Hoffer C; Sheffels P; Thummel K; Whittington D; Ensign D
Clin Pharmacol Ther; 2007 Oct; 82(4):410-26. PubMed ID: 17554244
[TBL] [Abstract][Full Text] [Related]
34. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.
Yates CR; Zhang W; Song P; Li S; Gaber AO; Kotb M; Honaker MR; Alloway RR; Meibohm B
J Clin Pharmacol; 2003 Jun; 43(6):555-64. PubMed ID: 12817518
[TBL] [Abstract][Full Text] [Related]
35. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
[TBL] [Abstract][Full Text] [Related]
36. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
37. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
[TBL] [Abstract][Full Text] [Related]
38. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
[TBL] [Abstract][Full Text] [Related]
39. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men.
Yang G; Fu Z; Chen X; Yuan H; Yang H; Huang Y; Ouyang D; Tan Z; Tan H; Huang Z; Zhou H
Clin Ther; 2011 Dec; 33(12):2060-70. PubMed ID: 22177374
[TBL] [Abstract][Full Text] [Related]
40. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]